Clinical

  1. Clinical

Alzheimer’s drug discovery foundation’s statement on FDA advisory committee’s endorsement of donanemab

NEW YORK, June 10, 2024. Today, the FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that donanemab shows clinical benefit for the treatment of early Alzheimer’s disease. If approved, donanemab would become the second disease-modifying drug for Alzheimer’s to receive full approval, expanding the arsenal of available drugs needed to treat Alzheimer’s […]
Written by
  1. Clinical

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials

DURHAM, N.C. and BEIJING, June 7, 2024. Brii Biosciences Limited (“Brii Bio,” “we,” or the “Company”), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, presented new data from two Phase 2 studies evaluating BRII-179 either as a combination therapy with BRII-835 (elebsiran) or as an add-on […]
Written by
  1. Clinical

AbbVie Announces Positive Topline Results from Phase 2 Trial Evaluating Elahere for High Folate Receptor-Alpha Expressing Platinum-Sensitive Ovarian Cancer

NORTH CHICAGO, Ill., June 6, 2024. AbbVie announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9% (95%CI 40.4 – 63.3%). […]
Written by
  1. Clinical

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

SOUTH SAN FRANSCISO, Calif., June 04, 2024. Surrozen, Inc. (“Surrozen” or the “Company”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis. The Phase 1b […]
Written by
  1. Clinical

Novartis Phase III Data Confirm Sustained Efficacy and Long-Term Safety of Oral Remibrutinib in Chronic Spontaneous Urticaria

Basel, May 31, 2024 – Novartis today announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU)1. In the pivotal Phase III studies, REMIX-1 and REMIX-2, remibrutinib treatment showed significant symptom improvement early, which was sustained up to Week 52, […]
Written by
  1. Clinical

Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV

HAYWARD, Calif., May 30, 2024. Avirmax Biopharma, Inc., a leading innovator in genetic medicines, is pleased to announce that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration (AMD) including Polypoidal […]
Written by
  1. Clinical

Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome

MELBOURNE, Australia, May 27, 2024. Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core […]
Written by
  1. Clinical

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

SOUTH SAN FRANCISCO, Calif., May 25, 2024. Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced positive results from a Phase 2 investigator-sponsored clinical trial of felzartamab for late antibody-mediated rejection (AMR) in kidney transplant recipients. Felzartamab is an investigational monoclonal antibody designed to […]
Written by
  1. Clinical

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of Afuresertib PLUS LAE001 for the Treatment of Prostate Cancer

SHANGHAI and WARREN, N.J., May 23, 2024. Laekna, Inc., a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 dual inhibitor) (“LAE201”)in patients with metastatic castration-resistant prostate cancer […]
Written by
  1. Clinical

New Results From Rilzabrutinib Phase 2 Study Show Potential to be First Advanced Oral Treatment for Moderate-to-Severe Asthma

Paris, May 22, 2024. Encouraging results from a phase 2 study showed that treatment with oral rilzabrutinib at both high dose and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma. These results were presented today […]
Written by

Good Reads

New Arabidopsis BIK1 Alleles Confirm Immunity Role

In a groundbreaking study poised to redefine our understanding of plant immunity, researchers have unveiled novel insights into the pivotal roles of the receptor-like cytoplasmic kinases BIK1 and PBL1 in Arabidopsis. These kinases, previously studied primarily through single transfer DNA (T-DNA) insertional mutant alleles, are reaffirmed as central players in the plant’s pattern-triggered immunity (PTI) […]
Written by

Climate Action Costs More in the Global South. Here’s Why. – State of the Planet

Clean energy technologies have become more affordable around the world. Yet for many countries in the Global South, the cost of transitioning to a low-carbon economy remains disproportionately high. But not because the equipment is more expensive: in fact, solar and wind components are often imported at comparable prices around the world, as global manufacturing scale and […]
Written by

Worlwide

New Arabidopsis BIK1 Alleles Confirm Immunity Role

In a groundbreaking study poised to redefine our understanding of plant immunity, researchers have unveiled novel insights into the pivotal roles of the receptor-like cytoplasmic kinases BIK1 and PBL1 in Arabidopsis. These kinases, previously studied primarily through single transfer DNA (T-DNA) insertional mutant alleles, are reaffirmed as central players in the plant’s pattern-triggered immunity (PTI) […]
Written by

Climate Action Costs More in the Global South. Here’s Why. – State of the Planet

Clean energy technologies have become more affordable around the world. Yet for many countries in the Global South, the cost of transitioning to a low-carbon economy remains disproportionately high. But not because the equipment is more expensive: in fact, solar and wind components are often imported at comparable prices around the world, as global manufacturing scale and […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.